Moleculin BIO - BIG Cancerpipeline ! LOW FLOAT (Seite 104)
eröffnet am 03.01.19 14:11:40 von
neuester Beitrag 03.12.22 16:35:13 von
neuester Beitrag 03.12.22 16:35:13 von
Beiträge: 1.131
ID: 1.295.482
ID: 1.295.482
Aufrufe heute: 0
Gesamt: 70.151
Gesamt: 70.151
Aktive User: 0
ISIN: US60855D3098 · WKN: A407S6 · Symbol: MBRX
4,3000
USD
-3,59 %
-0,1600 USD
Letzter Kurs 01:20:23 Nasdaq
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 10,500 | +63,81 | |
| 0,9300 | +54,46 | |
| 5,9299 | +42,55 | |
| 3,0800 | +38,12 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2600 | -19,29 | |
| 1,4300 | -24,34 | |
| 1,4700 | -27,76 | |
| 2,2000 | -31,25 | |
| 1,4400 | -49,21 |
Beitrag zu dieser Diskussion schreiben
Feedbackwann gibt es den mal wieder News
ist ja ne totale Luftnummer geworden.
Antwort auf Beitrag Nr.: 60.506.637 von Wolfirainbow am 07.05.19 15:51:36schaut euch mal dieses Volumen im Max-Chart monatlich an ... ohne Worte!
...macht Freude und wird auch gut aufgenommen...
HOUSTON, May 7, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. After receiving a single starting dose of 120 mg/m2 in the first cohort of the dose escalation phase of the trial, 2 of 3 patients treated responded sufficiently to qualify for a potentially curative bone marrow transplant. The results for all 3 patients were reviewed by the Safety Review Committee, which determined that no drug-related adverse events were observed that would prevent advancing the trial to the next higher dose level of 150 mg/m2. To date in the European trial, one patient experienced grade 2 mucositis (which resolved to grade 1 within 2 days) and no other adverse events related to Annamycin have been reported. No additional patient data have been developed in the Company's parallel US clinical trial, which is currently recruiting its second cohort to be given a dose level of 120 mg/m2 (the US trial started at a lower initial dose of 100 mg/m2).
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers. (PRNewsfoto/Moleculin Biotech, Inc.)
"The progress in Europe, specifically Poland, continues to be encouraging," commented Walter Klemp, Moleculin's Chairman and CEO. "In just a few months, we have completed the first cohort and we've seen a partial response from 2 out of 3 patients sufficient to qualify them for a potentially curative bone marrow transplant. It's important to remember that these are relapsed or refractory patients for whom the standard of care failed. So, to see this kind of response at the starting dose level in the dose-ranging phase, we believe is quite remarkable. And, although this data is still preliminary and may not be indicative of the ultimate outcome of the trial, the improvement in activity at 120 mg/m2 in Poland as compared with the 100 mg/m2 cohort in the US is consistent with our expectations for Annamycin."
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of highly resistant cancers. (PRNewsfoto/Moleculin Biotech, Inc.)
"The progress in Europe, specifically Poland, continues to be encouraging," commented Walter Klemp, Moleculin's Chairman and CEO. "In just a few months, we have completed the first cohort and we've seen a partial response from 2 out of 3 patients sufficient to qualify them for a potentially curative bone marrow transplant. It's important to remember that these are relapsed or refractory patients for whom the standard of care failed. So, to see this kind of response at the starting dose level in the dose-ranging phase, we believe is quite remarkable. And, although this data is still preliminary and may not be indicative of the ultimate outcome of the trial, the improvement in activity at 120 mg/m2 in Poland as compared with the 100 mg/m2 cohort in the US is consistent with our expectations for Annamycin."
Antwort auf Beitrag Nr.: 60.445.796 von gl_77 am 29.04.19 10:26:28@Bios-Gurus
https://www.fda.gov/drugs/development-resources/surrogate-en…
ist jemandem dieses FDA Programm bekannt?
https://www.fda.gov/drugs/development-resources/surrogate-en…
ist jemandem dieses FDA Programm bekannt?
Trading Spotlight
Antwort auf Beitrag Nr.: 60.442.949 von 2brix am 28.04.19 18:19:22
Welche angekündigte News denn ... alle Nachrichten waren schon vor dem CC bekannt ... hast du dir den CC einmal angehört?
Zitat von 2brix: Jup die angekündigte News, welche einfach ausgeblieben ist.
Welche angekündigte News denn ... alle Nachrichten waren schon vor dem CC bekannt ... hast du dir den CC einmal angehört?
Jup die angekündigte News, welche einfach ausgeblieben ist.
Antwort auf Beitrag Nr.: 60.425.973 von Stoxtrayder am 25.04.19 21:49:53
Welches geplantes Treffen mit der FDA?
Zitat von Stoxtrayder: Das geplante Treffen mit der FDA wird er wohl meinen?!
Welches geplantes Treffen mit der FDA?
Das geplante Treffen mit der FDA wird er wohl meinen?!
Antwort auf Beitrag Nr.: 60.423.786 von 2brix am 25.04.19 17:29:37
Welche News meinst Du?
Zitat von 2brix: und wo sind die angekündigten News von gestern geblieben?
Welche News meinst Du?
Durchsuchen
